Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
Nicola SquillaceElena RicciTiziana QuirinoAndrea GoriAlessandra BanderaLaura CarenziGiuseppe Vittorio De SocioGiancarlo OrofinoCanio MartinelliGiordano MadedduStefano RusconiPaolo MaggiBenedetto Maurizio CelesiaLaura CordierFrancesca VichiLeonardo CalzaKatia FalascaAntonio Di BiagioGiovanni Francesco PellicanòPaolo Bonfantinull nullPublished in: PloS one (2017)
A significant decline in eGFR was observed in patients initiating EVG/COBI/FTC/TDF in the first 6 months, with no significant worsening occurring at 12 months vs. 6 months of therapy. Patients with chronic HCV infection were at higher risk to develop abnormal liver tests.
Keyphrases
- end stage renal disease
- ejection fraction
- small cell lung cancer
- chronic kidney disease
- newly diagnosed
- public health
- peritoneal dialysis
- epidermal growth factor receptor
- oxidative stress
- clinical trial
- electronic health record
- randomized controlled trial
- study protocol
- patient reported outcomes
- human immunodeficiency virus
- open label
- big data
- antiretroviral therapy
- machine learning
- smoking cessation
- cell therapy
- placebo controlled